Obtaining scientific advice from drug regulators - the good, the bad and the ugly
This article was originally published in SRA
Regulators want pharmaceutical companies to seek scientific advice from them during product development. Critically, they say, getting insight from regulators early on can smooth the path to approval. For companies, however, it’s not that simple. Maureen Kenny reports on the debate.
Register for our free email digests: